Prestroke Antiplatelet Agents in First-Time Ischemic Stroke Are Related to Subtypes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Jin-Man | - |
dc.contributor.author | Cha, Jaehyung | - |
dc.contributor.author | Choi, Jungsoon | - |
dc.contributor.author | Eun, Mi-Yeon | - |
dc.contributor.author | Seo, Woo-Keun | - |
dc.contributor.author | Oh, Kyungmi | - |
dc.contributor.author | Cho, Kyung-Hee | - |
dc.contributor.author | Yu, Sungwook | - |
dc.date.accessioned | 2022-07-15T19:36:41Z | - |
dc.date.available | 2022-07-15T19:36:41Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2016-03 | - |
dc.identifier.issn | 0014-3022 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/155533 | - |
dc.description.abstract | Background: It is not well known whether prestroke antiplatelet agents (PAs) are associated with the subtypes of ischemic stroke. Methods: We screened patients in a hospital-based stroke registry. Patients who were admitted with a diagnosis of first-time ischemic stroke within 5 days of symptom onset were included. Ischemic stroke subtypes were classified in accordance with the Trial of ORG 10172 in Acute Stroke Treatment classification based on stroke mechanism: large-artery atherosclerosis (LA), cardioembolism (CE), small vessel occlusion (SVO), other determined (OC) or undetermined causes (UC). Multinomial logistic regression analyses were performed to evaluate the effect of PA on stroke subtypes before and after propensity score matching. Results: Among 3,025 patients, 748 (24.7%) were taking antiplatelet agents prior to stroke. After propensity score matching, 1,190 patients were ultimately included. The PA group was associated with strokes caused by SVO rather than LA in multinomial logistic regression of an unmatched dataset. However, multivariable analysis after propensity score matching demonstrated that PA use was associated with a higher probability of SVO and CE (OR 2.05, p < 0.001 and OR 1.62, p = 0.05, respectively) compared with LA. Conclusions: PAs were associated with specific index stroke subtypes. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | S. Karger AG | - |
dc.title | Prestroke Antiplatelet Agents in First-Time Ischemic Stroke Are Related to Subtypes | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Jungsoon | - |
dc.identifier.doi | 10.1159/000444295 | - |
dc.identifier.scopusid | 2-s2.0-84957882247 | - |
dc.identifier.wosid | 000371845100013 | - |
dc.identifier.bibliographicCitation | European Neurology, v.75, no.1-2, pp.89 - 95 | - |
dc.relation.isPartOf | European Neurology | - |
dc.citation.title | European Neurology | - |
dc.citation.volume | 75 | - |
dc.citation.number | 1-2 | - |
dc.citation.startPage | 89 | - |
dc.citation.endPage | 95 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.subject.keywordPlus | ASPIRIN RESISTANCE | - |
dc.subject.keywordPlus | INFARCT | - |
dc.subject.keywordPlus | LACUNAR | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | SEVERITY | - |
dc.subject.keywordPlus | PATTERNS | - |
dc.subject.keywordAuthor | Prestroke antiplatelet agents | - |
dc.subject.keywordAuthor | Ischemic stroke | - |
dc.subject.keywordAuthor | Subtypes | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.